UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

The anti-asthmatic drug, montelukast, modifies the neurogenic potential in the young healthy and irradiated brain

Eriksson, Y; Boström, M; Sandelius, A; Blennow, K; Zetterberg, H; Kuhn, G; Kalm, M; (2018) The anti-asthmatic drug, montelukast, modifies the neurogenic potential in the young healthy and irradiated brain. Cell Death & Disease , 9 , Article 775. 10.1038/s41419-018-0783-7. Green open access

[thumbnail of Zetterberg_The anti-asthmatic drug, montelukast, modifies the neurogenic potential in the young healthy and irradiated brain_VoR.pdf]
Preview
Text
Zetterberg_The anti-asthmatic drug, montelukast, modifies the neurogenic potential in the young healthy and irradiated brain_VoR.pdf - Published Version

Download (1MB) | Preview

Abstract

Brain tumors are the most common form of solid tumors in children. Due to the increasing number of survivors, it is of importance to prevent long-term treatment-induced side effects. Montelukast, a leukotriene receptor antagonist, may have the desired neuroprotective properties. The aim of the study was to determine whether montelukast could reduce adverse effects of cranial irradiation (CIR) to the young brain. Daily injections of montelukast or vehicle was given to young mice for 4 or 14 days in combination with CIR or under normal conditions. Montelukast treatment for 4 days protected against cell death with 90% more cell death in the vehicle group compared to the montelukast group 24 h after CIR. It also resulted in less microglia activation 6 h after CIR, where montelukast lowered the levels of CD68 compared to the vehicle groups. Interestingly, the animals that received montelukast for 14 days had 50% less proliferating cells in the hippocampus irrespective of receiving CIR or not. Further, the total number of neurons in the granule cell layer was altered during the sub-acute phase. The number of neurons was decreased by montelukast treatment in control animals (15%), but the opposite was seen after CIR, where montelukast treatment increased the number of neurons (15%). The results show beneficial effects by montelukast treatment after CIR in some investigated parameters during both the acute phase and with longer drug treatment. However, it also resulted in lower proliferation in the hippocampus under normal conditions, indicating that the effects of montelukast can be either beneficial or unfavorable, depending on the circumstances.

Type: Article
Title: The anti-asthmatic drug, montelukast, modifies the neurogenic potential in the young healthy and irradiated brain
Open access status: An open access version is available from UCL Discovery
DOI: 10.1038/s41419-018-0783-7
Publisher version: http://doi.org/10.1038/s41419-018-0783-7
Language: English
Additional information: © The Author(s) 2018. This article is licensed under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases
URI: https://discovery.ucl.ac.uk/id/eprint/10056843
Downloads since deposit
68Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item